Loading…
Employees: 632
Size AngioDynamics (ANGO) is a United States Health Care company (Medical Specialties) with a market value of $493M, the 2710th largest of 3,117 United States companies the cockpit tracks. Shares closed at $11.73 on 6 Nov 2026.
Performance Over six months the shares gained 4.7%, against -14.2% for the median peer and -1.1% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 8.2% over the last twelve months (peer median +0.7%); the operating margin is -6.0% (peer median 4.4%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 4.2× (2nd cheapest of 19).
Capital Return on invested capital runs 17.3 points below its cost of capital (6.3% WACC).
Short interest Short interest is 4.6% of the free float (15 Oct 2026).
Next results Next results expected around 7 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $325M | $320M | $292M | $304M | $339M |
| Revenue growth | — | +9% | -4% | -10% | — |
| Gross profit | $170M | $164M | $147M | $142M | $155M |
| EBITDA | $2.88M | -$1.15M | -$244,000 | -$6.10M | $14.5M |
| Net income | -$32.9M | -$36.7M | -$34.0M | -$184M | -$52.4M |
| Free cash flow | -$3.87M | -$2.86M | -$21.0M | -$35.7M | -$9.13M |
| Capital expenditure | $7.55M | $5.95M | $10.2M | $10.8M | $9.75M |
| Total debt | $10.7M | $11.0M | $3.95M | $5.91M | $55.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANGO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.5% | -5.9% | 5th highest of 21 |
| 6-month return | +4.7% | -14.2% | 8th highest of 21 |
| Distance from 52-week high | -28.0% | -35.1% | 8th highest of 21 |
| Revenue growth (TTM) | +8.2% | +0.7% | 4th highest of 21 |
| Operating margin | -6.0% | 4.4% | 7th lowest of 21 |
| EV / Sales | 1.4× | 4.2× | 2nd cheapest of 19 |
| ROIC minus cost of capital | -17.3 pp | -3.8 pp | 4th lowest of 19 |
| Net debt / EBITDA | -8.1× | -0.8× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AngioDynamics ANGO | United States | $493M | +5% | +8% | -6% | 1.4× | n/a | n/a |
| Revenio REG1V.HE | Finland | $494M | -22% | +16% | 14% | 5.5× | 19.3% | +12.4% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $499M | -14% | -9% | -51% | n/a | n/a | n/a |
| WELL LEAD MEDICAL 603309.SS | China | $486M | -19% | +1% | 15% | 2.0× | -5.6% | +7.7% |
| CellaVision CEVI.ST | Sweden | $485M | +68% | +2% | 23% | 6.0× | 6.5% | +10.0% |
| MiMedx MDXG | United States | $483M | -8% | -23% | -8% | 1.2× | 11.5% | +11.0% |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -12% | 7.5× | 35.5% | -6.9% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 13% | n/a | n/a | n/a |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 14% | 1.6× | n/a | n/a |
| AVITA Medical RCEL | United States | $513M | +304% | +1% | -47% | 7.3× | n/a | n/a |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 11% | 1.6× | 3.8% | -2.8% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 3% | 4.0× | 22.2% | -11.7% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | 6% | 3.5× | 6.7% | +0.3% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 11% | 5.2× | 22.1% | +2.2% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | 7.1× | 42.6% | +0.4% |
| Delcath Systems DCTH | United States | $518M | +30% | +36% | -2% | 4.5× | 10.1% | +120.2% |
| Guangdong Biolight Meditech 300246.SZ | China | $519M | -23% | +4% | -9% | 3.4× | 14.8% | -4.7% |
| Hangzhou Alltest Biotech 688606.SS | China | $521M | -15% | 0% | 13% | 1.6× | -3.9% | -4.3% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -106% | 20.2× | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +53% | -14% | 2% | 26.5× | n/a | n/a |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 6% | 1.5× | n/a | n/a |